How long does AB-FUBINACA last?

The total duration of AB-FUBINACA via smoked is 1 hour to 2 hours. Onset typically occurs within 20 minutes. Peak effects last 30 minutes to 1 hour.

AB-FUBINACA — SubstanceWiki

AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) is a synthetic cannabinoid receptor agonist belonging to the indazolecarboxamide chemical class. Originally developed by Pfizer in 2009 during cannabinoid receptor research, it was subsequently identified in herbal smoking mixtures and the illicit synthetic cannabinoid market beginning around 2012. AB-FUBINACA is a full agonist at both CB1 and CB2 cannabinoid receptors — a pharmacological distinction from THC's partial agonism that underpins its dramatically greater potency and toxicity profile.

Synthetic cannabinoids as a class represent among the most dangerous substances in the novel psychoactive substance landscape. Full CB1 agonism produces effects qualitatively unlike cannabis at equipotent doses: cardiovascular toxicity (tachycardia, bradycardia, chest pain, myocardial infarction), seizures, renal failure, acute psychosis, and deaths have all been documented. AB-FUBINACA specifically has been associated with multiple mass poisoning events, clustered hospitalization incidents, and fatalities. Its appearance in products marketed as "herbal incense," "spice," or "K2" means users frequently have no knowledge of its identity or dose.

How It Feels

AB-FUBINACA is one of the more potent synthetic cannabinoids, and its effects arrive with a force that can overwhelm even experienced cannabis users. Within moments of inhalation, a massive wave of sedation crashes through the body, pressing consciousness downward with an almost violent urgency. The transition from sober to profoundly altered happens so quickly that there is barely time to register the onset before the peak is already upon you. The eyes close involuntarily. The body goes slack.

The peak is dominated by an overwhelming sedation that goes far beyond the relaxed drowsiness of natural cannabis. This is not relaxation -- it is suppression, a pharmacological pressing-down of neural activity that leaves the mind functioning at a fraction of its normal capacity. Thoughts become sparse, separated by vast intervals of blankness. When they do appear, they are disjointed and hard to hold, slipping away like water through fingers. The emotional landscape is flat, evacuated of both anxiety and pleasure, leaving only a neutral warmth that lacks the richness and texture of natural cannabinoid experiences.

The body becomes extraordinarily heavy. Movement requires a deliberate effort that seems disproportionate to the task. Muscle coordination degrades sharply -- hands fumble, steps become uncertain, and the disconnect between the brain's commands and the body's execution widens into something almost comical if it were not also alarming. The heart rate increases significantly, sometimes dramatically, pounding in the chest with a force that can provoke anxiety even through the sedative fog. Nausea may surface, a queasy rolling in the stomach that threatens but does not always result in vomiting.

Visual and auditory perception are altered in ways that share some characteristics with cannabis but are amplified to uncomfortable extremes. Colors may appear oversaturated. Sounds echo or distort. There can be a sense of the visual field narrowing, tunnel vision closing in at the periphery, accompanied by a pressure behind the eyes that feels distinctly synthetic. Time distortion is profound and disorienting, each minute expanding to feel like many, the clock frozen in place.

The duration of intense effects is relatively short -- one to two hours -- but the comedown is rarely clean. As the peak subsides, it often leaves behind a persistent drowsiness, a headache, and a general sense of physical malaise that can last for hours. The appetite, suppressed during the peak by nausea, may rebound dramatically. Sleep comes easily but is often shallow and unrewarding, and the morning after carries a foggy, depleted quality that natural cannabis hangovers rarely match.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(11)

Appetite enhancement— A distinct increase in hunger and desire for food, often accompanied by enhanced enjoyment of taste ...
Changes in felt gravity— A distortion of one's proprioceptive sense of gravity in which the perceived direction of gravitatio...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...

Cognitive & Perceptual Effects

Visual(3)

Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
Visual haze— A translucent fog or haze overlays the visual field, softening the environment and reducing clarity....

Cognitive(9)

Anxiety

Detection Methods

Standard Drug Panel Inclusion

AB-FUBINACA is a synthetic cannabinoid receptor agonist that is not detected on standard 5-panel drug screens. Standard THC immunoassays target 11-nor-9-carboxy-THC (THC-COOH), the primary metabolite of delta-9-THC, and do not cross-react with synthetic cannabinoids. Some expanded drug panels (12-panel or custom panels) include a synthetic cannabinoid channel, but coverage of specific compounds varies widely between manufacturers.

Urine Detection

AB-FUBINACA and its metabolites can be detected in urine for approximately 2 to 5 days after a single use, though chronic heavy use can extend this window to 7 or more days. Synthetic cannabinoids undergo extensive hepatic metabolism, primarily via hydroxylation and carboxylation, producing metabolites that are excreted in urine as glucuronide conjugates. The specific metabolite profile varies by compound and is a key factor in whether a given immunoassay can detect AB-FUBINACA.

Blood and Saliva Detection

Blood concentrations of AB-FUBINACA decline rapidly after use, with a detection window of approximately 12 to 48 hours for the parent compound. Metabolites may persist longer. Oral fluid testing can detect parent compound and early metabolites for approximately 24 to 48 hours, and some roadside testing devices include synthetic cannabinoid panels.

Hair Follicle Detection

Hair follicle analysis can detect synthetic cannabinoids for up to 90 days. However, incorporation rates and detectability vary by compound. Some laboratories offer expanded hair panels that include common synthetic cannabinoids such as JWH-018 and AB-FUBINACA metabolites, but coverage of newer compounds including AB-FUBINACA may be limited.

Confirmatory Testing

LC-MS/MS is the preferred confirmatory method for synthetic cannabinoids. The structural diversity and rapid evolution of this substance class means that reference standards must be available for the specific compound under investigation. GC-MS can also be used but LC-MS/MS offers superior sensitivity and specificity for the typically low concentrations encountered. Both parent compound and key metabolites should be targeted.

Reagent Testing

Standard reagent tests (Marquis, Mecke, Mandelin) are generally uninformative for synthetic cannabinoids, as these compounds are typically applied to herbal material at very low concentrations and produce no characteristic color reactions. Visual inspection and reagent testing cannot distinguish treated herbal material from untreated plant matter. Immunoassay-based test strips specific to synthetic cannabinoids are available from some harm reduction suppliers and represent a more practical point-of-use screening option.

Interactions

Substance	Status	Note
1,3-Butanediol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
25E-NBOH	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
2C-T	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
2C-T-2	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
2C-T-21	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
2C-T-7	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
3-Cl-PCP	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
3-HO-PCE	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
3-HO-PCP	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
3-MeO-PCE	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
3-MeO-PCMo	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
3-MeO-PCP	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
4-MeO-PCP	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
Allylescaline	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Ayahuasca	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Cake	Caution	Increased sedation and cognitive impairment
Deschloroetizolam	Caution	Increased sedation and cognitive impairment
Deschloroketamine	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
DET	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Diclazepam	Caution	Increased sedation and cognitive impairment
Diphenidine	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
DiPT	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
DOM	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
DPT	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Efavirenz	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Ephenidine	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
EPT	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Eszopiclone	Caution	Increased sedation and cognitive impairment
Etizolam	Caution	Increased sedation and cognitive impairment
Flubromazepam	Caution	Increased sedation and cognitive impairment
Flubromazolam	Caution	Increased sedation and cognitive impairment
Flunitrazepam	Caution	Increased sedation and cognitive impairment
Flunitrazolam	Caution	Increased sedation and cognitive impairment
Gaboxadol	Caution	Increased sedation and cognitive impairment
HXE	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
Ibogaine	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Inhalants	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
Lorazepam	Caution	Increased sedation and cognitive impairment
Memantine	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
Mephenaqualone	Caution	Increased sedation and cognitive impairment
MET	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Methallylescaline	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Metizolam	Caution	Increased sedation and cognitive impairment
Midazolam	Caution	Increased sedation and cognitive impairment
MiPT	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
MPT	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
MXiPr	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
Nicotine	Caution	Increased sedation and cognitive impairment
Nifoxipam	Caution	Increased sedation and cognitive impairment
O-PCE	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
PCE	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
Pentobarbital	Caution	Increased sedation and cognitive impairment
Phenobarbital	Caution	Increased sedation and cognitive impairment
Psilocybin Mushrooms	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
SAMe	Caution	Increased sedation and cognitive impairment
Cocaine	Uncertain	—
DMT	Uncertain	—
LSD	Uncertain	—
Mescaline	Uncertain	—

Showing 59 key interactions out of 63 total.

Toxicity & Safety

Life-Threatening Toxicity

AB-FUBINACA and other indazolecarboxamide synthetic cannabinoids have caused confirmed fatalities and numerous near-fatal events. The toxicity profile differs qualitatively from cannabis intoxication:

Cardiovascular: Tachycardia, bradycardia, chest pain, ST-segment changes, myocardial infarction, and cardiac arrest have been documented. Young, otherwise healthy users have experienced cardiac events attributed directly to AB-FUBINACA toxicity.

Neurological: Seizures, status epilepticus, loss of consciousness, and coma. Acute psychotic episodes with agitation, paranoia, and violence that may persist beyond acute intoxication.

Renal: Acute kidney injury and renal failure — a toxicity not associated with THC and believed to reflect off-target effects of synthetic cannabinoid metabolites.

Respiratory: Respiratory depression and aspiration pneumonia in severe toxicity.

Mass Poisoning Events

AB-FUBINACA was responsible for a documented mass poisoning event in New York City in 2016, when 33 people were hospitalized in a single day from use of synthetic cannabinoid products containing it. This event is cited in public health literature as a case study in the mass-casualty potential of potent synthetic cannabinoids.

No Antidote

There is no specific pharmacological antidote for synthetic cannabinoid toxicity. Treatment is supportive. Cannabis-derived CBD or THC may theoretically modulate CB1 signaling but has not been established as effective rescue treatment.

Addiction Potential

moderately addictive with a high potential for abuse

Overdose Information

overdose will cause physical discomfort including heart palpitations, vertigo and sedation at much lower than dangerous doses, usually causing the user to suffer large amounts of anxiety or to fall asleep.

It is worth noting that this compound has been linked to multiple hospitalizations and deaths due to its use.

It has often been recommended that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly increase one's current state of mind and emotions. Also, like THC, prolonged usage of synthetic cannabinoids may increase one's disposition to mental illness and psychosis, particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).

As synthetic cannabinoids are active in the milligram range (with below 5mg being a typical dose), it is important to use proper precautions when dosing to avoid a negative experience.

It is strongly recommended that one use harm reduction practices when using this drug.

As with other synthetic cannabinoids, the chronic use of AB-moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of AB-develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). AB-FUBINACA presents cross-tolerance with Cross-all cannabinoids, meaning that after the consumption of AB-FUBINACA all cannabinoids will have a redu

Full	develops with prolonged and repeated use
Half	3 - 7 days
Zero	1 - 2 weeks

AB-FUBINACA

Quick Dosage

Dosage

smoked

Duration

smoked

How It Feels

Subjective Effects

Physical Effects

Physical(11)

Cognitive & Perceptual Effects

Visual(3)

Cognitive(9)

Pharmacology

Mechanism of Action: Full vs. Partial CB1 Agonism

Receptor Profile

Potency

Detection Methods

Standard Drug Panel Inclusion

Urine Detection

Blood and Saliva Detection

Hair Follicle Detection

Confirmatory Testing

Reagent Testing

Interactions

History

Pfizer Origins

Entry Into Illicit Markets

Regulatory Response

Harm Reduction

Primary Recommendation: Avoid

If Use Occurs

Emergency Response

Testing Limitations

Toxicity & Safety

Life-Threatening Toxicity

Mass Poisoning Events

No Antidote

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (4)

See Also

References (4)

Frequently Asked Questions

Auditory(2)